KPV: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published preclinical research on KPV (Lys-Pro-Val), the C-terminal tripeptide fragment of alpha-MSH, including anti-inflammatory mechanisms, gut mucosal research findings, and sourcing considerations for Canadian researchers.
What Is KPV?
KPV (Lys-Pro-Val) is a tripeptide representing the C-terminal amino acid sequence (positions 11–13) of alpha-melanocyte stimulating hormone (α-MSH). α-MSH is a 13-amino acid neuropeptide derived from the proopiomelanocortin (POMC) precursor protein and is well characterized for its anti-inflammatory activity via melanocortin receptor signaling. KPV retains significant anti-inflammatory activity despite its minimal size, making it a useful research tool for studying the active pharmacophore of the α-MSH molecule.
KPV research has focused primarily on gut mucosal inflammation, macrophage biology, and NF-κB pathway modulation. Its small size enables investigation of nanoparticle-based delivery systems and direct mucosal application in gastrointestinal research models. All material supplied by ACCUTIDE is for laboratory research use only (RUO).
Proposed Mechanisms of Action
MC1R Agonism and NF-κB Inhibition
KPV activates melanocortin receptor 1 (MC1R) expressed on macrophages, dendritic cells, and intestinal epithelial cells. MC1R activation via Gs protein coupling elevates intracellular cAMP and activates downstream signaling that inhibits the NF-κB transcription factor, reducing expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β.
Direct Epithelial Cell Targeting
Unlike many anti-inflammatory peptides with primarily systemic mechanisms, KPV research has demonstrated direct effects on intestinal epithelial cells independent of immune cell intermediaries. This direct epithelial targeting makes KPV particularly relevant for gut mucosal inflammation research and local delivery studies.
Neutrophil Chemotaxis Inhibition
KPV and its parent peptide α-MSH have been documented to inhibit neutrophil chemotaxis via MC1R expressed on neutrophil surfaces. This mechanism is relevant to acute inflammatory models where neutrophil recruitment to tissue injury sites is a key endpoint.
Nanoparticle Delivery Compatibility
The tripeptide size of KPV (MW 354 Da) makes it well-suited for encapsulation in polymer nanoparticle delivery systems for oral or mucosal administration research. Studies have documented significantly enhanced therapeutic indices for nanoparticle-KPV versus free peptide in experimental colitis models.
Selected Published Research
The following is a selection of peer-reviewed studies available in PubMed. All studies listed involve preclinical animal models or in vitro research. This is not a comprehensive literature review.
Dalmasso G, et al. — Inflammatory Bowel Diseases, 2008
Demonstrated that KPV directly targets intestinal epithelial cells and macrophages to downregulate NF-κB signaling and reduce pro-inflammatory cytokine production, with effects comparable to full-length α-MSH in colitis models.
Kannengiesser K, et al. — Regulatory Peptides, 2008
Examined KPV-mediated anti-inflammatory effects in LPS-stimulated macrophage cultures and murine colitis models, documenting reduction of TNF-α, IL-6, and IL-1β via NF-κB inhibition.
Bhardwaj RS, et al. — Peptides, 1997
Identified MC1R expression on neutrophils and documented α-MSH and its C-terminal KPV fragment as inhibitors of neutrophil chemotaxis, suggesting a role in modulating acute inflammatory cell recruitment.
Laroui H, et al. — Gastroenterology, 2010
Developed and tested a nanoparticle delivery system for KPV in mouse colitis models, demonstrating significant reduction in colon inflammation markers and improvement in histological scores following oral nanoparticle-KPV administration.
Purity Standards for Research Use
HPLC Purity Analysis
Research-grade KPV should meet ≥99%+ purity by HPLC. Given the small tripeptide size, the chromatographic profile must confirm absence of dipeptide or single amino acid impurities that would arise from incomplete synthesis.
Mass Spectrometry (Identity)
MS confirms the correct molecular weight (354 Da) and fragmentation for KPV (Lys-Pro-Val), distinguishing it from structurally related tripeptide sequences. Identity confirmation is particularly important for small peptides where near-identical molecular weights are common.
Endotoxin Testing
Endotoxin testing (LAL method) is essential for KPV research given its study context in inflammatory models. LPS is a potent NF-κB activator that would directly confound results in cytokine and macrophage activation studies.
Certificate of Analysis (COA)
Batch-specific COA documenting HPLC purity, MS identity, and endotoxin results. Required for institutional procurement and critical for gastrointestinal and immunology studies where source material quality directly affects reproducibility.
Sourcing KPV in Canada
ACCUTIDE Research Supply provides KPV tested to ≥99%+ HPLC purity with batch-specific COA documentation. All material is lyophilized for stability and ships Canada-wide. For research use only.
KPV — Canadian Research Supply
HPLC tested · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Kpv in preclinical research literature.
Research Use Only Disclaimer: All information on this page is provided for scientific research and educational purposes only. KPV supplied by ACCUTIDE Research Supply is strictly for laboratory and research use (RUO). It is not intended for human or animal consumption, therapeutic use, or any application outside of controlled research settings. All published studies referenced are preclinical or in vitro research. Findings must not be extrapolated to human use.